Ghayath Janoudi
@janoudi.bsky.social
Augmented Intelligence Clinical Discovery™ and Evidence Synthesis
I've studied AI extensively, I dislike using the term. Too much noise obscuring AI true purpose. In medicine, AI is a tool that needs standard measures for diagnosis & therapy (e.g. positive and negative predictive value). Treating AI as a mere tool, not an alien concept, will expedite its adoption.
Ghayath Janoudi on LinkedIn: An AI revolution is brewing in medicine. What will it look like?
If you know me, you know I don't really like to say the words Artificial Intelligence or AI. But do you know why?
It’s not because I don't think this is an…
www.linkedin.com
October 25, 2023 at 8:28 PM
I've studied AI extensively, I dislike using the term. Too much noise obscuring AI true purpose. In medicine, AI is a tool that needs standard measures for diagnosis & therapy (e.g. positive and negative predictive value). Treating AI as a mere tool, not an alien concept, will expedite its adoption.
In car shops, fixing 1 car out of 10 is unacceptable. So why do we accept a 90% failure rate in clinical trials?
Because we focus on patents, not patients. To enhance success rates, we must normalize and streamline clinical discovery, evidence synthesis, and generation. Prioritize patients, not IP!
Because we focus on patents, not patients. To enhance success rates, we must normalize and streamline clinical discovery, evidence synthesis, and generation. Prioritize patients, not IP!
Ghayath Janoudi on LinkedIn: What’s the parallel between car shops and drug development?
“This ...
What’s the parallel between car shops and drug development?
“This car shop is fantastic! Out of every 10 cars they see, they're able to fix 1.” said no one…
www.linkedin.com
October 25, 2023 at 2:41 AM
In car shops, fixing 1 car out of 10 is unacceptable. So why do we accept a 90% failure rate in clinical trials?
Because we focus on patents, not patients. To enhance success rates, we must normalize and streamline clinical discovery, evidence synthesis, and generation. Prioritize patients, not IP!
Because we focus on patents, not patients. To enhance success rates, we must normalize and streamline clinical discovery, evidence synthesis, and generation. Prioritize patients, not IP!